darunavir/ritonavir QD + raltegravir BID — Competitive Intelligence Brief

darunavir/ritonavir QD + raltegravir BID (darunavir/ritonavir QD + raltegravir BID) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protease inhibitor and integrase strand transfer inhibitor. Area: Infectious Diseases.

phase 3 Protease inhibitor and integrase strand transfer inhibitor HIV protease and HIV integrase Infectious Diseases Small molecule

Target snapshot

darunavir/ritonavir QD + raltegravir BID (darunavir/ritonavir QD + raltegravir BID) — ANRS, Emerging Infectious Diseases. Darunavir/ritonavir QD is a protease inhibitor that blocks HIV replication, while raltegravir BID is an integrase strand transfer inhibitor that also blocks HIV replication.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
darunavir/ritonavir QD + raltegravir BID TARGET	darunavir/ritonavir QD + raltegravir BID	ANRS, Emerging Infectious Diseases	phase 3	Protease inhibitor and integrase strand transfer inhibitor	HIV protease and HIV integrase
atazanavir/raltegravir	atazanavir/raltegravir	Community Research Initiative of New England	marketed	Antiretroviral combination (protease inhibitor + integrase inhibitor)	HIV protease and HIV integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protease inhibitor and integrase strand transfer inhibitor class)

1. ANRS, Emerging Infectious Diseases · 1 drug in this class